Unigene Laboratories Inc.

News - Unigene Laboratories Inc.

Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies

2012-05-22 02:27:56

BOONTON, N.J., May 22, 2012 /PRNewswire/ -- Unigene Laboratories, Inc.

Unigene to Present at TIDES 2012

2012-05-21 02:25:36

BOONTON, N.J., May 21, 2012 /PRNewswire/ -- Unigene Laboratories, Inc.

Unigene Announces First Quarter 2012 Financial Results

2012-05-07 02:32:43

BOONTON, N.J., May 7, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced financial results for the first quarter ended March 31, 2012.

Unigene's Proprietary Oral Peptide Delivery Platform is Further Validated with Cara Therapeutics' Successful Completion of its Phase 1 Study Using Unigene's Oral Formulation of Novel Kappa Opioid Receptor Agonist, CR845

2012-04-03 02:27:43

BOONTON, N.J., April 3, 2012 /PRNewswire/ -- Unigene Laboratories, Inc.

Unigene Appoints Jack Wyszomierski to its Board of Directors

2012-04-02 02:29:04

BOONTON, N.J., April 2, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics today

More News (49 articles) »

News - Unigene Laboratories Inc.

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health